Developing new therapies for traumatic central nervous system injuries
NurExone Biologic Inc. , an innovative biotech company pioneering exosome based therapies designed to help patients recover from traumatic central nerve system injuries.
There's a lot happening at NurExone from the formation of a US subsidiary and a new CEO to lead that subsidiary to their plans for uplisting to a major US exchange and recent funding activity. Lyndsay Malchuk recently caught up with CEO, Dr.Lior Shaltiel to an inside scoop on some exciting preclinical results and an upcoming scientific report that can mark a major step in the research development.
The following is a transcription of the above video, and The Market Online has edited it for clarity .
Lyndsay: I think the best place to actually start is with that US subsidiary. So tell us maybe a little bit about Exo-Top and can you tell us about the new Exo-Top CEO?
Lior: Yes. So let's start with the context. We bought just recently in the end of last year, huge assets, which is the master cell bank in the US, a former US company. And these assets will stay in the US and this is the reason that we open the subsidiary there. The aim of the subsidiary is first of all to hold the master cell bank, develop it to a working cell bank and produce naive exosomes, which is the first step of our therapy for NurExone's supply, NurExone Ltd for further research and development for clinical phase. And because we are sitting on large assets, also offer exosomes in the highest standards as a B2B business for cosmetic, aesthetic and other vendors that would like to purchase it.
Regarding the CEO, I'm very glad to have Jacob Licht on our Board. He came with more than 25 years of experience in a large pharmaceutical, including a lot of experience in operations and M&A. I think that bring NurExone to a new level. Speaking American and not just entrepreneurship Israelis.
Lyndsay: Let's peel back just a little bit more here if we can. Now you've engaged with a number of North American investment banks in order to achieve that US exchange listing. So my question is, what can you share about that process, where it stands and what it means for NurExone's next phase of growth?
Lior: Sure. So, we completed in April a $2.3 million Canadian dollar raise. We are well funded with the back wind of a very successful JP Morgan event in San Francisco. We got a lot of the attention from US and Canadian investment banks. And our plan is now to up list NurExone from Canada to a major stock exchange in the US in order to be in the right market. Because as you know, the majority of large pharmaceuticals that got into a clinic need to be on a major stock exchange with the support of the market and the liquidity. And we will get the support from these investment banks to raise in two steps pre IPO raise and after that a full IPO to a major stock exchange in the US.
Lyndsay: How do you plan to use the funds to work and are you looking at any additional support from the government for grants in Israel?
Lior: Yes, we are looking all the time non-governmental funds. We have interest from the Israeli defense ministry in order to apply NurExone products in the battlefield. I believe that it'll also be relevant for the US DOD, (Department of Defense). So non-governmental is of course one of the sources to support NurExone. But on top of that, as I said, we would like to use the raise now and the raise that we completed in April in order to proceed into a clinical stage company and provide all the necessary IND enabling study in order to submit it to the FDA.
Lyndsay: I'm going to flip over here to go over some preclinical information that's exciting as well. So, the latest preclinical results around the ExoPTEN look really promising when it comes to improving motor function. So for you, what stood out in the findings? I mean, how does this move the needle for your research?
Lior: That's a very good point. We changed models at NurExone, moving from a very, very severe and not physiological model, which is full transection the spinal cord, which we could see a motor sensoric and bladder functional recovery. But now we move to a more physiological in order to get more physiological data in a compression model, meaning that you're pressing the nerves and not cutting it.
That's more of a fit to what happens to a human when you have an injury. And we see even stronger recovery. Okay. If you take a scale, the scale of motor recovery is even higher when you use the therapy. So this gives us a lot of hope that we are in the right direction. On top of that, we have also the results that we are getting more and more rats into the optic nerve damage showing the same strong recovery after just 18 days in an ERG. I think we are on the right track. We need to make sure that we have the whole package that the necessary for the FDA in order to translate our company to a clinical stage company.
Lyndsay: Let's lean into that research further. I know that there's a scientific report that's coming out soon as well. So how big of a moment is that for you and what kind of response are you hoping for from regulators or investors or even potential partners?
Lior: The correspondence with the FDA is critical. So one of the things that we want to keep is the dialogue. The last one that we had is in the end of 2023 when we completed the pre-IND. Since then we had a lot of progress. Our research became even more advanced, the production that we do in the 3D bioreactors is getting more advanced. So we have more questions today to the FDA and when sharing that we are getting ourself more focus, what is the right track? So, keeping the dialogue is critical and we are working with the regulator to help us bring the therapy further into a clinical stage.
NurExone Biologic's website is nurexone.com and you can find them on the Venture Exchange under the ticker symbol NRX.
Join the discussion: Find out what everybody's saying about this stock on the NurExone Biologic investor discussion forum, and check out the rest of Stockhouse's stock forums and message boards.
The material provided in this article is for information only and should not be treated as investment advice. For full disclaimer information, please click here
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Ottawa Citizen
an hour ago
- Ottawa Citizen
Ottawa's $11-billion infrastructure gap: Here's what you need to know
Article content City staff are proposing water rate hikes and taking on more debt to address a $10.8-billion 'gap' between infrastructure needs and available funds over the next 10 years. Article content Staff presented councillors with 12 'asset management plans' (AMPs) that outline critical information on all municipal assets — from transportation services to wastewater and stormwater infrastructure to emergency and protective services — worth approximately $90 billion. Article content Article content Article content The plans offer 'a clear view' of the current state of Ottawa's infrastructure, which, according to a staff report, 'is safe, in good to fair condition, and continues to serve residents.' Article content Article content What is the funding gap? Article content 'These forecasted needs reflect asset renewal, growth, service enhancements, and climate change adaptation and mitigation costs,' according to the staff report. Article content 'A measured backlog is expected in a large and established municipal portfolio, and the city has a strong track record of managing these challenges … Ottawa is experiencing a trend seen in all Canadian municipalities — a growing infrastructure backlog, largely driven by aging assets, the effects of climate change, rising construction costs and a limited number of revenue sources.' Article content Article content Article content The city will need $4.8 billion over the next 10 years for 'priority needs' in repairing and refurbishing water, wastewater and stormwater infrastructure. Article content Staff presented councillors with a long-range financial plan for wastewater and stormwater that calls for rate increases between 4.5 and 5.6 per cent annually over the next decade at an average of 5.0 per cent per year. That equates to about five dollars more per month for the average residential home. Article content Mayor Mark Sutcliffe told councillors that it would be considered 'good debt' at the June 3 finance and corporate services committee. Article content 'The way we use debt, I think, would fall into the category of good debt in the sense that we're not using debt to pay for our yearly operating expenses, we are using debt to pay for long-term investments in assets that will generate benefit to the community for many, many years to come,' Sutcliffe said.
Japan Forward
2 hours ago
- Japan Forward
Fuji Media Turns to Shimizu for Post-Scandal Overhaul
このページを 日本語 で読む Fuji Media Holdings (FMH) new president, Kenji Shimizu, is pledging sweeping reforms to restore trust and reinvent the business after an industry scandal earlier this year. The network was rocked in January by a scandal involving former pop idol Masahiro Nakai, which exposed an opaque corporate culture at Fuji TV Fuji's initial closed-door handling of the misconduct allegations drew intense public criticism, forcing an open apology and a third-party probe into the company's governance. The fallout prompted a broad shake-up of Fuji's leadership and internal policies, including the resignation of top executives and the appointment of Shimizu as president to lead an urgent reform effort In a candid interview with The Sankei Shimbun , Shimizu, set to take over as president of FMH on June 25, acknowledged deep-rooted issues at the heart of recent scandals. He outlined a reform agenda aimed at restoring trust and revitalizing Fuji's content business. At the core of the recent problems, said Shimizu, was the "rigidity and homogeneity" in Fuji's personnel system. Over time, this led to an environment where "no one could speak up, even when they sensed something was wrong." He pointed to structural reforms already underway, including a reconstituted board with a majority of independent outside directors and a higher ratio of women. These, he said, would significantly improve governance transparency. When asked about the lingering influence of Hisashi Hieda, the former chairman who served for over 40 years on the board, Shimizu dismissed concerns. "There is absolutely no influence from Mr Hieda on the new leadership team," he affirmed. He added that Fuji has introduced stricter retirement policies and abolished its advisor system to ensure board independence. Kenji Shimizu, President of Fuji TV, during an interview (©Sankei by Yasuhiro Yajima). On the decision to reject a shareholder proposal from the American investment fund Dalton Investments, Shimizu said the company conducted interviews with all director candidates, including those proposed by Dalton, and applied the same selection process. "We saw no reason to increase the board size or change direction. The current team offers both balance and effectiveness." Asked whether profits from Fuji's real estate division have led to complacency in the media arm, Shimizu defended the group's strategy. The real estate and tourism businesses have evolved dramatically, he noted. But the real issue is the "low profitability of media content," which he intends to address head-on. Reflecting on past missteps, Shimizu admitted that Fuji "hasn't done enough to monetize its content." He said the company needs to move away from planning shows just for TV broadcast and start designing projects with broader revenue streams in mind, from streaming and theatrical releases to merchandising and gaming. "If we stop assuming terrestrial TV is the default outlet, our creative horizons will widen." Shimizu emphasized that his ultimate goal as president is for Fuji to grow while contributing to society. "Profit is just a means," he said. "A company that doesn't help solve social problems or improve something has no reason to exist." Drawing on his background in anime production, Shimizu said he never saw animation as something just for children. "Kids are sharp," he explained. "They don't fall for cheap tricks. They evaluate entertainment honestly." Producing Dragon Ball and Chibi Maruko-chan, he said, taught him valuable lessons about pacing, emotional storytelling, and understanding an audience. He recalled how Dragon Ball captivated viewers with its explosive speed — "a new villain appears, and by the next panel, he's already sliced down." With Chibi Maruko-chan, the challenge was entirely different: bringing to life a still world frozen in the psychological landscape of author Momoko Sakura. To preserve that vision, he built a writing team of women from the same generation as Sakura. Shimizu also discussed managing the fallout of the recent scandal. Fuji has done everything possible to avoid passing costs onto its affiliates or production partners, he noted. Even when sponsors pulled out, Fuji continued to fully fund production. "Supporting our partners and stakeholders is a responsibility we won't compromise on," he said. Interview by Katsutoshi Takagi Author: The Sankei Shimbun このページを 日本語 で読む
Canada Standard
3 hours ago
- Canada Standard
Minister Sidhu champions rules-based trade with Canada's Organisation for Economic Co-operation and Development and World Trade Organization partners
June 5, 2025 - Paris, France - Global Affairs Canada The Honourable Maninder Sidhu, Minister of International Trade, this week concluded his participation in the Organisation for Economic Co-operation and Development (OECD) Ministerial Council Meeting (MCM) and World Trade Organization (WTO) mini-ministerial meeting, in Paris, France. At the OECD MCM, Minister Sidhu reaffirmed Canada's support for the rules-based global trading system and its underpinning values. These include reinforcing the open, stable markets that ensure predictability amidst economic uncertainty, responsibly developing artificial intelligence and standing up for Ukraine. Canada served as vice-chair of the OECD MCM alongside Australia and Lithuania, under the chairship of Costa Rica. At the meeting, Canada and the Philippines formally took on the role of the 2025 to 2028 co-chairs of the OECD Southeast Asia Regional Programme (SEARP), a program that was created to address economic and development challenges in Southeast Asia. Minister Sidhu announced that Canada will contribute $2 million to support SEARP's activities, which align with Canada's Indo-Pacific Strategy and Strategic Partnership with ASEAN. At the WTO mini-ministerial meeting, Minister Sidhu advocated for deep and meaningful reforms of the WTO to ensure its rules are modernized and continue to support a rules-based global trading system. Canada also called for a pragmatic approach to the WTO's 14th Ministerial Conference that considers current economic challenges. While in Paris, the Minister also hosted a business round table with Canadian companies active in the French market. As Canada seeks to strengthen its collaboration with reliable trading partners, the Minister heard the business representatives' first-hand perspectives on the opportunities for Canadian businesses in France.
